Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Unlock the editor’s digest in free
FT editor Raula Khalaf selected his favorite stories in this weekly newsletter.
The Swiss Pharma Group Novartis says they will expand its US production and research and development with $ 23 billion in investment for more than five years, as pharmaceutical manufacturers will configure their supply chains as part of a potential US tariff preparation.
Novartis, who produces various drugs from cancer to cardiovascular drug, says investments will enable it to produce all its US drugs in the country. It will create seven new benefits and expand the other.
Vas Narasimhan, CEO NovartisIt is said that investments reflect the “pro-pro-policy and regulatory environment in the United States that supports our ability to find the progress of subsequent treatment for patients”.
The announcement has been the latest investment by a major drug company since Donald Trump won the presidential election. Indianapolis -based Eli Lily declared $ 27 billion of investment plans In February, Johnson and Johnson, the headquarters in New Jersey, said last month that it would invest more than $ 55 billion in four factories. Astrazenca said in November that it would invest $ 3.5 billion in the United States.
The Pharmaceutical industry Last week, Snakes announced by Trump were relieved of the global tariff. However, the administration has indicated that they will be imposed soon.
Novartis assumes that investments will create about a thousand jobs in the company and will be more than 4,000 in supply chains and communities. It will also invest in the United States to produce active pharmaceutical elements, a region where this industry is very dependent on supply from China and India.
The company will establish a $ 1.1BN Research and Development Institute in San Diego, it is second in the United States after the existing facilities in the Boston region. It will expand the production facilities for radioligand therapy by expanding the factory that already produces treatment in Indiana, New Jersey and California, in Florida and Texas.
Narasimhan said that this company was “fully confident” in its guideline for the year “prepare to shift in the external environment” and “completely confident” and at least 40 percent of the original margin of 2027, with its guidance.
